Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Body mass index between 18 and 34, inclusive.~* Based on sleep history, has had chronic insomnia for at least 3 months.~* Based on sleep history, reports a subjective sleep latency greater than or equal to 45 min and a subjective total sleep time less than or equal to 6.5 hours.~* Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM.~* Mean latency to persistent sleep of greater than 20 minutes on two consecutive screening nights with neither night less than 15 minutes. Also, a mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes.~* Based on sleep history, normally uses pharmacological assistance to sleep 0 to 4 times per week in the last 3 months.~Exclusion Criteria~* Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds.~* Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.~* Sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication.~* Flown across greater than three time zones within 7 days prior to or during screening.~* Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication.~* Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease or fibromyalgia.~* History of psychiatric disorder within the past 6 months.~* History of alcohol abuse within the past 12 months, as defined in Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within 24 hours of any polysomnogram visits.~* History of drug abuse within the past 12 months, as defined in Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition Revised.~* Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication.~* Apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night.~* Periodic Leg Movement Syndrome with arousal index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night.~* Positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment visits.~* Positive breathalyzer test on any of the polysomnogram assessment visits.~* Uses tobacco products (including nicotine gum and patch) or any other products that may interfere with the sleep wake cycle during nightly awakenings.~* Used any central nervous system medication or other drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of single-blind study medication. These medications must not have been used to treat psychiatric disorders.~* Intends to continue taking any disallowed medication or any prescription medication or over the counter medication that is known to affect the sleep/wake function or otherwise interfere with evaluation of the study medication. The subject must report all prescription and over the counter medications taken in the three weeks prior to screening.~* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~  * Anxiolytics~ * Sedatives~ * Hypnotics~ * CNS active drugs (including herbal)~ * Antidepressants~ * Narcotic analgesics~ * Anticonvulsants~ * Beta blockers~ * Sedating H1 antihistamines~ * St. John's Wort~ * Systemic steroids~ * Kava-kava~ * Respiratory stimulants~ * Ginkgo-biloba~ * Decongestants~ * Over-the-counter and prescription stimulants~ * Antipsychotics~ * Over-the-counter and prescription diet aids~ * Muscle Relaxants~ * Melatonin and all other drugs or supplements known to affect sleep/wake function~* Any additional condition(s) that in the Investigator's opinion would~  * affect sleep/wake function~ * prohibit the subject from completing the study~ * indicate that continuation in the study would not be in the best interests of the subject.~* History of hepatitis B or hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramelteon 8 mg QD (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete